BioSpace News Archive

The Government of Canada is committed to protecting the health and safety of all Canadians while ensuring economic resilience and contributing to the international response to COVID-19. Since the outbreak of COVID-19, the government has been working closely with industry to understand which areas require urgent investment while building dome

In response to the second wave of COVID-19 in Canada and the risk it represents for the mental health and well-being of working populations, EQ Care is recognizing the immediate needs of needs of the Canadians

BioAgilytix is thrilled to announce the addition of a new diagnostics tool to their growing list of cutting-edge bioanalysis instruments. The Phadia™ 200 is a powerhouse of a machine, in a compa

An investigational drug for the treatment of Alzheimer’s disease shows significant improvement for patients with Lewy body dementia in a clinical trial that includes participants at the Pacific Neuroscience Institute located at Providence Saint John’s Health Center.

American Diabetes Month™ will kick off next week, and the American Diabetes Association® is asking the diabetes community to rise up! Right now, everything seems to be conspiring to try to make us feel powerless, afraid and small.

Humanigen, Inc. (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with lenzilumab, today announced that MedStar Washington Hospital Center in Washington, D.C. treated its first COVID-19 patient with lenzilumab

Mylan N.V. and Pfizer Inc. announced that the U.S. Federal Trade Commission accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business.

QIAGEN today announced a non-exclusive agreement with Phase Genomics, Inc. to license specific patents to sell its EpiTect Hi-C kits in the United States.

3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced Scott Dylla, Ph.D has joined its Board of Directors.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, November 5, 2020 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter and nine months ended September 30, 2020 and to provide a business update.